Meeting
2014 ASCO Annual Meeting
The role of CHFR as a predictive marker of response to taxane-based preoperative chemotherapy in triple-negative breast cancer.
Authors
Elisavet Paplomata
Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
Elisavet Paplomata , Gabriel Sica , Shahrzad Ehdaivand , Dana Nickleach , Yuan Liu , Amelia Bruce Zelnak , Ruth O'Regan , Johann Christoph Brandes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1112)
DOI
10.1200/jco.2014.32.15_suppl.1112
Abstract #
1112
Poster Bd #
205
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2018 ASCO Annual Meeting
Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.
First Author: Sandra M. Swain
Poster
2018 ASCO Annual Meeting
Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial.
First Author: Jose Bines
Poster
2015 ASCO Annual Meeting
Transcriptomic and protein expression analysis of helicase antigen (HAGE) in triple negative breast cancer (TNBC) as a novel prognostic and predictive biomarker.
First Author: Tarek M. A. Abdel-Fatah